Emergency hospitalizations for unsupervised prescription medication ingestions by young children

Pediatrics

Volumn 134, Issue 4, 2014, Pages e1009-e1016

  Lovegrove, Maribeth C ^a   Mathew, Justin ^b   Hampp, Christian ^b   Governale, Laura ^b,c   Wysowski, Diane K ^b   Budnitz, Daniel S ^a  

^a NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^c ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENERGIC RECEPTOR BLOCKING AGENT; AMFEBUTAMONE; AMLODIPINE; AMPHETAMINE DERIVATIVE; ANTICONVULSIVE AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUPRENORPHINE; BUPRENORPHINE PLUS NALOXONE; CALCIUM CHANNEL BLOCKING AGENT; CLONAZEPAM; CLONIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLIBENCLAMIDE; GLIPIZIDE; GUANFACINE; HYDROCODONE; LISINOPRIL; LORAZEPAM; METHYLDOPA; METOPROLOL; MUSCLE RELAXANT AGENT; NARCOTIC ANALGESIC AGENT; OXYCODONE; PRESCRIPTION DRUG; SEROTONIN UPTAKE INHIBITOR; SULFONYLUREA DERIVATIVE;

ARTICLE; CHILD; CHILD HOSPITALIZATION; CONTROLLED STUDY; DRUG SURVEILLANCE PROGRAM; EMERGENCY CARE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICATION ERROR; PRESCHOOL CHILD; PRESCRIPTION; PRIORITY JOURNAL; UNITED STATES; UNSUPERVISED MEDICATION INGESTION; CLINICAL TRIAL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; EMERGENCY HEALTH SERVICE; HOSPITALIZATION; INFANT; MULTICENTER STUDY; TRENDS;

ADVERSE DRUG REACTION REPORTING SYSTEMS; CHILD, PRESCHOOL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; EMERGENCY SERVICE, HOSPITAL; FEMALE; HOSPITALIZATION; HUMANS; INFANT; MALE; PRESCRIPTION DRUGS;

EID: 84925546130     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2014-0840     Document Type: Article

References (38)

1. Rodgers GB. The safety effects of childresistant packaging for oral prescription drugs: two decades of experience. JAMA. 1996;275(21):1661-1665
2. US Consumer Product Safety Commission. Poison Prevention Packaging: A Guide for Healthcare Professionals. Washington, DC: US Consumer Product Safety Commission; 2005
3. Budnitz DS, Salis S. Preventing medication overdoses in young children: an opportunity for harm elimination. Pediatrics. 2011;127(6). Available at: www.pediatrics.aappublications. org/content/127/6/e1597.full
4. Bronstein AC, Spyker DA, Cantilena LR Jr, Rumack BH, Dart RC. 2011 Annual report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 29th annual report. Clin Toxicol (Phila). 2012;50(10):911-1164
5. Bronstein AC, Spyker DA, Cantilena LR Jr, Green JL, Rumack BH, Dart RC. 2010 Annual report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 28th annual report. Clin Toxicol (Phila). 2011;49(10):910-941
6. Bond GR, Woodward RW, Ho M. The growing impact of pediatric pharmaceutical poisoning. J Pediatr. 2012;160(2):265-270.e1
7. 16 CFR x 1700.1 Subchapter E-Poison Prevention Packaging Act Of 1970 Regulations, Part 1700-Poison Prevention Packaging. 38 FR 21247, Aug. 7, 1973, as amended at 41 FR 22266, June 2, 1976; 48 FR 57480, Dec. 30, 1983
8. Lavonas EJ, Banner W, Bradt P, et al. Root causes, clinical effects, and outcomes of unintentional exposures to buprenorphine by young children. J Pediatr. 2013;163(5): 1377-1383.e1-e3
9. Schoenewald S, Ross S, Bloom L, et al. New insights into root causes of pediatric accidental unsupervised ingestions of overthe-counter medications. Clin Toxicol (Phila). 2013;51(10):930-936
10. Lembersky RB, Nichols MH, King WD. Effectiveness of child-resistant packaging on toxin procurement in young poisoning victims. Vet Hum Toxicol. 1996;38(5):380-383
11. Jacobson BJ, Rock AR, Cohn MS, Litovitz T. Accidental ingestions of oral prescription drugs: a multicenter survey. Am J Public Health. 1989;79(7):853-856
12. Budnitz DS, Lovegrove MC. The last mile: taking the final steps in preventing pediatric pharmaceutical poisonings. J Pediatr. 2012;160(2):190-192
13. Schillie SF, Shehab N, Thomas KE, Budnitz DS. Medication overdoses leading to emergency department visits among children. Am J Prev Med. 2009;37(3):181-187
14. Jhung MA, Budnitz DS, Mendelsohn AB, Weidenbach KN, Nelson TD, Pollock DA. Evaluation and overview of the National Electronic Injury Surveillance System-Cooperative Adverse Drug Event Surveillance Project (NEISS-CADES). Med Care. 2007;45(10 suppl 2):S96-S102
15. Budnitz DS, Pollock DA, Weidenbach KN, Mendelsohn AB, Schroeder TJ, Annest JL. National surveillance of emergency department visits for outpatient adverse drug events. JAMA. 2006;296(15):1858-1866
16. IMS Health. Vector One National (VONA). January 2007 through December 2011. Accessed August 2013
17. IMS Health. Vector One Total Patient Tracker (TPT). January 2007 through December 2011. Accessed September 2013
18. Schroeder T, Ault K. The NEISS Sample (Design and Implementation): 1997 to Present. Washington, DC: US Consumer Product Safety Commission; 2001
19. Kish L. Survey Sampling. New York, NY: Wiley Interscience; 1995
20. 16 CFR x 1700.14 Subchapter E-Poison Prevention Packaging Act Of 1970 Regulations, Part 1700-Poison Prevention Packaging. 38 FR 21247, Aug. 7, 1973, as amended at 41 FR 22266, June 2, 1976; 48 FR 57480, Dec. 30, 1983
21. Bar-Oz B, Levichek Z, Koren G. Medications that can be fatal for a toddler with one tablet or teaspoonful: a 2004 update. Paediatr Drugs. 2004;6(2):123-126
22. Michael JB, Sztajnkrycer MD. Deadly pediatric poisons: nine common agents that kill at low doses. Emerg Med Clin North Am. 2004;22(4):1019-1050
23. Poison Prevention Week Council. [Poison-Prevention.org Web site]. Available at: www. poisonprevention.org/index.htm. Accessed March 18, 2014
24. National Capital Poison Center. Quills up-stay away! Available at: www.poison.org/prevent/preschool.asp. Accessed March 18, 2014
25. Burghardt LC, Ayers JW, Brownstein JS, Bronstein AC, Ewald MB, Bourgeois FT. Adult prescription drug use and pediatric medication exposures and poisonings. Pediatrics. 2013;132(1):18-27
26. Wang GS, Le Lait MC, Heard K. Unintentional pediatric exposures to central alpha-2 agonists reported to the National Poison Data System. J Pediatr. 2014;164(1):149-152
27. Lung DD, Olson KR. Hypoglycemia in pediatric sulfonylurea poisoning: an 8-year poison center retrospective study. Pediatrics. 2011; 127(6). Available at: www.pediatrics.org/cgi/ content/full/127/6/e1558
28. Bailey JE, Campagna E, Dart RC; RADARS System Poison Center Investigators. The underrecognized toll of prescription opioid abuse on young children. Ann Emerg Med. 2009;53(4):419-424
29. Centers for Disease Control and Prevention. Buprenorphine prescribing practices and exposures reported to a poison center-Utah, 2002-2011. MMWR Morb Mortal Wkly Rep. 2012;61(49):997-1001
30. Kim HK, Smiddy M, Hoffman RS, Nelson LS. Buprenorphine may not be as safe as you think: a pediatric fatality from unintentional exposure. Pediatrics. 2012;130 (6). Available at: www.pediatrics.org/cgi/ content/full/130/6/e1700
31. Centers for Disease Control and Prevention. Emergency department visits and hospitalizations for buprenorphine ingestion by children-United States, 2010-2011. MMWR Morb Mortal Wkly Rep. 2013;62(3):56
32. Lovegrove MC, Hon S, Geller RJ, et al. Efficacy of flow restrictors in limiting access of liquid medications by young children. J Pediatr. 2013;163(4):1134-1139.e1
33. Consumer Healthcare Products Association. OTC industry announces voluntary transition to one concentration of single-ingredient pediatric liquid acetaminophen medicines [press release]. Washington, DC: Consumer Healthcare Products Association; May 4, 2011. Available at: www.chpa.org/05-04-11-PedAcet.aspx. Accessed March 18, 2014
34. Institute for Safe Medication Practices. Simple packaging change can reduce Rx drug diversion. Available at: www.consumermedsafety. org/medication-safety-articles/item/721-simplepackaging-change-can-reduce-rx-drug-diversion. Accessed May 24, 2014
35. Reckitt Benckiser Pharmaceuticals. Reckitt Benckiser Pharmaceuticals Inc. to voluntarily discontinue the supply of suboxone tablets (buprenorphine and naloxone sublingual tablets [CIII]) [press release]. Reckitt Benckiser Pharmaceuticals, Inc; September 25, 2012. Available at: www.rb.com/site/rkbr/templates/ mediainvestorsgeneral2.aspx?pageid=1328&& cc=gb. Accessed May 27, 2014
36. Orexo AB. Orexo provides update on reimbursement and launch preparations for Zubsolv [press release]. Uppsala, Sweden: Orexo AB; September 5, 2013. Available at: www.orexo.com/en/Investor-Relations/Pressreleases/?guid=803851. Accessed March 18, 2014
37. Drugs@FDA. Silver Spring, MD: US Food and Drug Administration; 2014. Available at: www. accessdata.fda.gov/scripts/cder/drugsatfda/ index.cfm. Accessed June 5, 2014
38. US Food and Drug Administration. Currently approved shared system REMS. Available at: www.fda.gov/drugs/drugsafety/postmarket drugsafetyinformationforpatientsandproviders/ ucm111350.htm#Shared. Accessed March 18, 2014